Introduction
Genetic predisposition to breast cancer is a major risk factor in women. Factors contributing to this predisposition at both the population and molecular genetic levels are poorly understood at present. Progress is, however, being made both through the study of the population genetics of families with high incidences of breast cancer and the cytogenetic and molecular characterization of human breast carcinomas. For example, we recently cytogenetically characterized a large series of untreated human breast carcinomas and found 3 of 44 with clonal karyotypic changes. A young woman with bilateral carcinomas had a 3p deletion in one tumor, while two other tumors had transitions involving chromosome 1 (1) . It has been suggested that these sorts of chromosomal changes are associated with the loss of suppressor gene activity or the activation of certain oncogenes (2) .
Most ofthe suppressor genes and oncogenes that have been identified in human tumors have been largely conserved through eukaryotic evolution. Based on this, we are attempting to identify genes that modulate human breast carcinogenesis by characterizing potential homologues in lower mammals. We chose this path of investigation because of the relative ease of genetically characterizing species that can be both selectively and rapidly bred. The animal model chosen was the rat, with many inbred strains available for study. The rat was chosen over the mouse because a) mammary cancers in the rat, like the human but unlike the mouse, lack a major viral etiology, b) tumors of the rat, unlike the mouse, are readily induced by chemicals, radiation, or hormonal treatments, and c) the rat mammary tumor resembles that of the human in its spectra of hormonal responsiveness. Unfortunately, the rat has a much less characterized genomic map than does the mouse.
Rat Strain Susceptibility
Rat types (outbred) and strains (inbred) differ in their susceptibilities to both spontaneous and induced mammary cancers. We have recently reviewed the susceptibility of many rat strains to spontaneous and induced mammary tumors (3) . The susceptibility of a rat strain to spontaneous carcinomas cannot be predicted by its susceptibility to induced cancer. In previously reviewing the incidence of various spontaneous tumors in different rat strains, we found a strong correlation between the propensity of a specific strain to develop prolactin-secreting pituitary tumors and its likelihood to develop mammary carcinomas (3) . This association is mechanistically reasonable, since prolactin has been shown to be a promoter of rat mammary carcinogenesis (4, 5) . Thus, increased susceptibility to spontaneous mammary cancer is probably controlled via an abscopal mechanism related to hyperplastic and neoplastic changes in the prolactin-secreting cells of the anterior pituitary. The propensity of a rat to develop pituitary cell transformation is genetically controlled in an additive fashion by approximately three independently segregating genes (6) .
In general, rat strains fall into three susceptibility groups for the development of induced mammary carcinomas. The first group has a high incidence of tumors following carcinogen administration (e.g., Wistar-Furth [WF]), while the second is totally resistant (e.g., Copenhagen [Cop] ). The third group, which includes the Fischer (F344) rat, has an intermediate susceptibility ( Figs. 1 and 2) . We determined the genetic basis for these three categories of rats by segregation analysis. WF rats from the high susceptibility group ofrat strains were bred to F344 rats from the intermediate susceptibility group of strains. We tested parent strains as well as F1, F2, and backcross rats for the development of mammary carcinomas following exposure to the mammary carcinogen 7,12-dimethylbenz[a]anthracene (DMBA). We found that each group of hybrid rats was phenotypically very similar to the more susceptible parent strain, the WF rat (7) (Fig. 1 ). These data suggested that the susceptibility-conferring factor in the WF rat was controlled by multiple, independently segregating genes. The action of these genes was not additive, in that rats with one or more of these genes had equal susceptibility to DMBA-induced mammary tumors. When various genetic models were fit to the data, we found that the one suggesting three independently segregating genes fit best. Further experiments in which the sexes of the strains in the analysis were reversed suggested that these genes were not sex linked and that maternal factors or genetic imprinting was not a factor. Whether each independently segregating susceptibilityconferring gene is the same or different remains to be determined. The genetic composition of rats in the second category, which are completely resistant to both induced and spontaneous mammary tumors, was also tested by segregation analysis. Resistant Cop rats were bred with susceptible WF rats. Parent strains, F1, F2, and backcross hybrid rats were treated with DMBA and followed for the development of mammary carcinomas (Fig. 2) . The results of this analysis suggest that the resistance to mammary carcinogenesis found in the Cop rat is due to a single autosomal dominant gene (3) . A similar conclusion was reached by Isaacs, 
Site of Expression
In order to begin to characterize the function of these genes as well as to develop strategies to clone them, we sought to determine their organ/tissue site of expression and action. We approached this question for both the susceptibility (7) and MCS genes (9) by constructing and testing chimeric rats. Chimeric rats are constructed by grafting known numbers of clonogenic mammary cells from donor rats to ectopic sites such as the interscapular white fat pad of recipient rats (10) . Here the clonogenic cells divide and redifferentiate to structurally and functionally normal mammary tissue (11) . In these assays, the recipient rats are usually F1 hybrids of two inbred strains. Thus, it is possible to graft tissue from either parent strain into the F1 recipient rats.
To determine if the susceptibility genes carried by the WF rat are active within the mammary parenchyma or abscopally active such as in the immune or endocrine system, WF-F344 chimerics were constructed and tested. WF x F344 F1 hybrids received ectopic mammary grafts from either F344 or WF rats. After ectopic glands differentiated from these transplanted cells, the recipient hybrid rats were given DMBA, and tumors developing in the ectopic sites were followed by weekly palpation. If the WF susceptibility genes were active in host systems such as the endocrine system, then it would be predicted that both F344 and WF ectopic mammary glands should develop equal numbers of tumors since they developed in identical F1 hosts. On the other hand, if the WF susceptibility genes were active within the mammary parenchyma, then it would be predicted that more carcinomas should develop in the WF ectopic glands. The results supported the latter prediction, in that more tumors developed in the WF ectopic glands when compared to equivalent ectopic F344 (Fig. 4) . These data suggest that the main suppressor activity associated with the Cop rat resides in the mammary parenchyma. However, a small amount of suppressor activity is also expressed abscopally. This 
Gene Function
The rat MCS gene is organ-specific in its action. Dunning and Curtis showed that the chemical carcinogens whose action was suppressed in the Cop mammary gland could cause tumors in other organs such as the liver in this rat strain (12) . We extended these observations by investigating the activity of the Cop MCS gene in inhibiting various DMBA-induced epithelial pathologies in the rat mammary gland. In the experiments described above, our results were based on the development of palpable carcinomas at the ectopic mammary graft sites. DMBA-exposed graft sites not developing carcinomas were prepared for whole mount observation. Lesions found in the whole mounts were removed and sectioned for histopathological study. Two nonpalpable epithelial lesions were found. These were small mammary carcinomas termed microcarcinomas (Fig. 6 ) and focal alveolar hyperplasias (FAH) (Fig. 7) .
Lesions were compared in DMBA-treated WF ectopic mammary glands growing in WF x F344 versus those growing in WF x Cop hybrid recipient rats. We found equal frequencies of microcarcinomas in WF glands in both recipient types (Fig. 8) , indicating that the MCS gene does not affect microcarcinomas at the host level. However, when Cop cells were grafted into WF x Cop, no microcarcinomas were found (Fig. 9 ). Together these data suggest that the MCS gene inhibits the development of microcarcinomas and that its action in this regard is totally mediated within the mammary parenchyma (9) .
In contrast to the activity of the MCS in inhibiting microcarcinomas, we found that this gene had no influence on the development of FAH. We compared the frequency of FAH developing in DMBA-treated ectopic WF and Cop mammary glands growing in WF x Cop hosts. No statistically significant difference was found in the frequencies of FAH developing in Cop and WF glands (9) (Fig. 9) .
We next asked if the MCS gene product acted in a paracrine manner, with the MCS gene product secreted by the mammary cells into the extracellular space followed by binding of the MCS product to mammary cell surface receptors. Such a paracrine mechanism has been demonstrated in human mammary tumors for growth factors such as transforming growth factor x and ,B (13 not significantly differ in the frequency of carcinomas formation, while both frequencies were much greater than that found in the Cop mammary ectopic glands (Fig. 5) We are currently attempting to further characterize the function of both the susceptibility and MCS genes. For example, we and others have been unable to induce mammary carcinomas in Cop rats by a wide variety of physical, chemical, and hormonal carcinogens. We are currently attempting to overcome this MCS-induced resistance by introducing a series of activated oncogenes into the mammary epithelium of Cop and control strain rats. Defining oncogenes that can and cannot bypass the suppressor function of the MCS gene will aid us in understanding the mechanism of MCS action. Finally, we are also currently involved in devising strategies to molecularly clone and characterize the MCS gene. We are currently evaluating both subtraction hybridization and insertional mutagenesis as a means to achieve this goal.
